Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

OBJECTIVE: Having demonstrated short-term weight loss with liraglutide in this group of obese adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for sustaining weight loss (secondary outcome) over 2 years. DESIGN: A randomized, double-blind, placebo-controlled 20-we...

Descripción completa

Detalles Bibliográficos
Autores principales: Astrup, A, Carraro, R, Finer, N, Harper, A, Kunesova, M, Lean, M E J, Niskanen, L, Rasmussen, M F, Rissanen, A, Rössner, S, Savolainen, M J, Van Gaal, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374073/
https://www.ncbi.nlm.nih.gov/pubmed/21844879
http://dx.doi.org/10.1038/ijo.2011.158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374073/
https://www.ncbi.nlm.nih.gov/pubmed/21844879
http://dx.doi.org/10.1038/ijo.2011.158

Ejemplares similares